Check a paper's claims against linked experiments, exact results, stated scope, and limitations.Know what falsifiable science actually supports before you trust the answer.
Press Enter β΅ to search evidence
Explore by Goal
"The most beautiful experience we can have is the mysterious."
- Albert Einstein
Quick Answer
Copied
This 1982 single-patient report found that real hemodialysis (but not sham dialysis) significantly improved severe oral tardive dyskinesia in a 50-year-old woman with schizophrenia (blind-rater sign test, P=.002), coinciding with a 38% drop in dialysate beta-endorphin (2,287 to 1,432 pg/L), but symptoms relapsed about two weeks after discharge .
Long Answer
What the Authors Reported
In a double-blind study of hemodialysis for schizophrenia, a 50-year-old woman with 20 years of illness and severe orofacial tardive dyskinesia (movements severe enough that nurses feared oral thermometer breakage) underwent two sham and two real dialyses in randomized order . Key quantitative results:
Sham dialyses: minimal improvement lasting <72 hours, then return to baseline.
Real dialyses: marked improvement in oral movements, apparent to staff and family; remission of hallucinations; discharge symptom-free without medication β but most psychiatric and neurologic symptoms returned ~2 weeks after discharge.
Dialysate beta-endorphin (RIA): 2,287 pg/L (first dialysis) falling to 1,432 pg/L (second), a 38% reduction the authors used to argue endorphin system hyperactivity in tardive dyskinesia .
Blinded videotape rating: 16 raters (9 psychiatrists, 7 nonpsychiatrists) correctly preferred post-real-dialysis segments (sign test for matched pairs, P=.002).
Critical Appraisal
The paper has genuine methodological strengths for its era: a randomized double-blind sham-controlled design within a single patient, standardized Feighner criteria, independent psychiatric diagnosis by three clinicians, blinded structured rating of 30-second videotape pairs with internal controls, and empirical biochemical assay . However, the inferential leaps are substantial:
n=1 with no effect size or rater agreement data. P=.002 on a sign test over pooled rater judgments does not quantify clinical magnitude, and rater concordance is unreported.
The beta-endorphin inference is logically weak. A lower second-dialysis beta-endorphin level could reflect dialysis kinetics, assay variability across the two-step desalting procedure, or time β the paper provides no sham-dialysate endorphin comparison, no plasma values, and no dose-response relationship. The authors themselves note naloxone was ineffective in tardive dyskinesia in prior work yet still endorse the endorphin hypothesis .
Transient benefit undermines therapeutic relevance. Relapse within roughly four weeks of initial dialysis, despite the "remarkable" acute response, suggests any effect was short-lived and could reflect fluctuating dyskinesia severity, drug-washout dynamics (six weeks off antipsychotics), or spontaneous remission β all plausible without dialysis-specific mechanisms.
Historical context: hemodialysis for schizophrenia was a 1970s hypothesis that later rigorous controlled trials did not support; this sub-study inherits that failed research program's assumptions. Confounds include medication withdrawal itself, which can transiently mask or unmask dyskinesia, and the Hawthorne effects of intensive hospitalization.
Confidence: The reported observations (improvement after real dialysis, endorphin levels, P value) are what the paper states; the causal attribution to endorphin elimination is an unverified author interpretation with weak supporting logic. What would change the conclusion: replicated sham-controlled trials in multiple TD patients with plasma AND dialysate endorphin sampling, standardized AIMS ratings, and longer follow-up β none of which emerged favorably for the dialysis-schizophrenia program.
Placement in the TD Treatment Literature
Subsequent TD intervention studies faced the same reproducibility problem this case foreshadows: cholinergic agents (lecithin, deanol) showed no significant benefit across 11 randomized trials (261 patients) ; case-level signals like zolpidem and clozapine's 87.5% ESRS reduction over 5 years illustrate how single-arm TD reports often fail replication β the same epistemic risk applies to the hemodialysis case. Modern mechanistic work (basal ganglia structural changes and maladaptive plasticity ) shifted TD etiology toward dopamine receptor supersensitivity and structural change β frameworks that make a dialyzable blood-borne toxin explanation implausible for most TD cases.
Author Reviews:
Feedback:
Updated: November 21, 2026
BGPT Paper Review
Study Novelty
70%
First (and apparently only) reported hemodialysis-induced TD improvement with a sham-controlled within-patient design; novel for 1982 but embedded in the later-discredited schizophrenia-dialysis program.
Scientific Quality
30%
Thoughtful design for a case report (blinding, randomization, sham control), but n=1, no effect size, no rater agreement data, no sham-dialysate endorphin control, and a causal endorphin inference drawn from two uncontrolled assays; transient relapse undercuts the therapeutic claim.
Study Generality
20%
Findings from one woman with severe orofacial TD cannot generalize; the mechanistic hypothesis was never validated and is inconsistent with modern basal-ganglia/plasticity models of TD.
Study Usefulness
20%
Of mainly historical value; hemodialysis is not a viable TD therapy, and the endorphin mechanism was contradicted by subsequent naloxone trial failures. Illustrative for case-report methodology critique.
Study Reproducibility
30%
Methods (RIA procedure, rating paradigm) are described in enough detail to replicate, but reproduction requires the same rare phenotype, dialysis access, and a program of research that was not sustained.
Explanatory Depth
30%
Offers a superficial mechanistic story (endorphin elimination) without plasma controls, dose-response, or receptor-level evidence; acknowledges etiologic uncertainty but overinterprets two dialysate values.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
Dopaminergic hypersensitivity as the sole TD mechanism: zuclopenthixol/haloperidol crossover data showing equivalent TD suppression by D1/D2 vs D2 blockade and no withdrawal aggravation argue DA supersensitivity is not the major driver in all TD patients.
'Dialysis removes a schizophrenia toxin' (the parent 1970s hypothesis): abandoned after rigorous controlled trials failed to replicate early uncontrolled enthusiasm β the TD sub-claim inherits this graveyard status.